Haemonetics Corporation (HAE) Income Statement Analysis

See more : Apollo Hospitals Enterprise Limited (APOLLOHOSP.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Alaska Communications Systems Group, Inc. (ALSK) Income Statement Analysis – Financial Results
Jiin Yeeh Ding Enterprises Corp. (8390.TWO) Income Statement Analysis – Financial Results
Tecstar Technology Co., Ltd. (3117.TWO) Income Statement Analysis – Financial Results
Xunlei Limited (XNET) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL) Income Statement Analysis – Financial Results

Haemonetics Corporation (HAE)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.haemonetics.com

About Haemonetics Corporation

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991
Revenue	1.31B	1.17B	993.20M	870.46M	988.48M	967.58M	903.92M	886.12M	909.68M	910.37M	938.51M	891.99M	727.84M	676.69M	645.43M	597.88M	516.44M	449.61M	419.73M	383.60M	364.23M	336.96M	319.97M	293.86M	277.92M	282.10M	285.80M	309.80M	278.20M	262.40M	248.40M	216.30M	176.40M	157.30M
Cost of Revenue	617.51M	553.56M	487.69M	472.63M	503.97M	550.04M	492.02M	507.62M	503.80M	475.96M	470.14M	463.86M	358.60M	321.49M	307.95M	289.71M	258.72M	222.31M	199.20M	185.72M	192.11M	182.26M	165.14M	126.95M	121.70M	124.00M	127.10M	137.80M	110.50M	103.90M	94.20M	88.80M	78.50M	0.00
Gross Profit	691.55M	615.10M	505.50M	397.84M	484.51M	417.54M	411.91M	378.49M	405.87M	434.42M	468.37M	428.13M	369.24M	355.21M	337.48M	308.17M	257.73M	227.30M	220.54M	197.88M	172.12M	154.70M	154.83M	166.91M	156.22M	158.10M	158.70M	172.00M	167.70M	158.50M	154.20M	127.50M	97.90M	157.30M
Gross Profit Ratio	52.83%	52.63%	50.90%	45.70%	49.02%	43.15%	45.57%	42.71%	44.62%	47.72%	49.91%	48.00%	50.73%	52.49%	52.29%	51.54%	49.90%	50.56%	52.54%	51.58%	47.26%	45.91%	48.39%	56.80%	56.21%	56.04%	55.53%	55.52%	60.28%	60.40%	62.08%	58.95%	55.50%	100.00%
Research & Development	54.44M	50.13M	46.80M	32.86M	30.88M	35.71M	39.23M	37.56M	45.57M	54.19M	54.20M	48.64M	36.80M	32.66M	26.38M	23.86M	24.32M	23.88M	26.52M	19.99M	17.79M	19.51M	19.51M	19.04M	14.93M	15.10M	17.90M	19.00M	18.50M	16.70M	15.80M	0.00	0.00	0.00
General & Administrative	424.68M	369.48M	335.16M	271.49M	295.38M	293.78M	313.42M	299.23M	320.07M	335.19M	363.24M	314.21M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	7.10M	7.20M	4.40M	2.70M	4.30M	4.50M	3.10M	2.50M	3.90M	4.50M	3.60M	4.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	431.78M	376.68M	339.56M	274.19M	299.68M	298.28M	316.52M	301.73M	323.97M	339.69M	366.84M	318.81M	245.26M	213.90M	214.48M	198.74M	163.12M	137.07M	121.35M	118.04M	108.45M	97.71M	88.87M	86.73M	82.76M	86.70M	86.90M	92.30M	81.80M	75.70M	75.90M	77.20M	61.00M	0.00
Other Expenses	40.45M	32.26M	47.41M	32.83M	50.60M	0.00	0.00	-8.10M	87.67M	5.44M	1.71M	-6.54M	0.00	-1.89M	13.34M	0.00	0.00	-5.48M	-26.35M	-100.00K	0.00	0.00	0.00	4.61M	24.91M	24.60M	22.90M	12.30M	13.10M	13.70M	10.70M	8.50M	7.00M	0.00
Operating Expenses	526.67M	459.06M	433.78M	339.88M	330.56M	333.99M	355.75M	339.28M	369.54M	393.88M	421.04M	367.45M	282.06M	244.66M	240.86M	222.60M	187.44M	155.48M	121.52M	137.93M	126.24M	117.22M	108.39M	110.39M	122.59M	126.40M	127.70M	123.60M	113.40M	106.10M	102.40M	85.70M	68.00M	0.00
Cost & Expenses	1.14B	459.06M	921.47M	812.50M	834.53M	884.03M	847.77M	846.90M	873.34M	869.83M	891.18M	831.31M	640.67M	566.15M	548.81M	512.31M	446.15M	377.79M	320.72M	323.66M	318.35M	299.48M	273.52M	237.34M	244.29M	250.40M	254.80M	261.40M	223.90M	210.00M	196.60M	174.50M	146.50M	0.00
Interest Income	0.00	13.00M	5.80M	9.40M	13.50M	9.91M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	384.00K	399.00K	1.97M	0.00	7.86M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	13.02M	14.63M	17.12M	16.83M	16.20M	9.91M	4.53M	8.10M	9.47M	9.38M	10.93M	6.54M	0.00	6.00K	742.00K	64.00K	0.00	97.00K	0.00	0.00	0.00	0.00	13.58M	59.39M	13.10M	0.00	74.90M	0.00	0.00	0.00	0.00	1.60M	1.60M	0.00
Depreciation & Amortization	97.22M	93.31M	97.75M	84.29M	110.29M	109.42M	89.25M	89.73M	89.91M	86.05M	81.74M	65.48M	49.97M	48.15M	43.24M	36.46M	31.20M	27.50M	25.15M	27.58M	30.15M	28.43M	25.62M	24.50M	24.91M	24.60M	22.90M	12.30M	13.10M	13.70M	10.70M	8.50M	7.00M	0.00
EBITDA	265.58M	249.34M	178.50M	142.25M	264.24M	192.96M	153.03M	70.35M	45.97M	125.72M	127.04M	124.58M	139.46M	158.23M	125.25M	121.53M	101.48M	101.10M	124.17M	87.52M	77.44M	65.91M	72.06M	81.02M	73.13M	51.20M	53.90M	72.00M	67.40M	66.10M	62.50M	50.30M	36.90M	157.30M
EBITDA Ratio	20.29%	21.34%	17.06%	16.34%	26.73%	19.94%	16.09%	14.55%	13.89%	4.45%	5.04%	6.80%	11.66%	23.51%	15.03%	20.74%	19.27%	22.23%	22.63%	22.78%	20.60%	18.85%	25.00%	34.44%	23.56%	18.15%	26.91%	18.30%	23.08%	24.43%	24.07%	23.16%	20.58%	100.00%
Operating Income	164.88M	156.03M	80.75M	57.96M	153.95M	83.55M	56.16M	-19.38M	-43.98M	40.54M	47.33M	56.44M	88.76M	110.55M	83.28M	85.57M	70.29M	62.75M	99.02M	59.94M	45.88M	37.48M	36.45M	13.42M	33.63M	31.70M	31.00M	48.40M	54.30M	52.40M	51.80M	41.80M	29.90M	157.30M
Operating Income Ratio	12.60%	13.35%	8.13%	6.66%	15.57%	8.63%	6.21%	-2.19%	-4.84%	4.45%	5.04%	6.33%	12.19%	16.34%	12.90%	14.31%	13.61%	13.96%	23.59%	15.63%	12.60%	11.12%	11.39%	4.57%	12.10%	11.24%	10.85%	15.62%	19.52%	19.97%	20.85%	19.33%	16.95%	100.00%
Total Other Income/Expenses	-13.02M	-14.63M	-17.12M	14.95M	-16.20M	-9.91M	3.48M	-8.10M	-97.14M	-9.38M	-10.93M	-6.54M	740.00K	-467.00K	-2.01M	-565.00K	7.02M	9.59M	7.86M	-102.00K	-65.00K	1.13M	2.06M	3.91M	3.25M	969.00K	-26.50M	2.30M	900.00K	100.00K	-1.00M	-1.80M	-2.20M	-157.30M
Income Before Tax	151.87M	141.40M	63.63M	72.91M	87.15M	73.63M	59.63M	-27.48M	-53.46M	31.17M	36.40M	49.90M	89.50M	110.08M	81.27M	85.00M	77.30M	72.34M	106.88M	59.84M	45.81M	38.61M	38.51M	17.33M	27.33M	32.60M	4.50M	50.70M	55.20M	52.50M	50.80M	40.00M	27.70M	0.00
Income Before Tax Ratio	11.60%	12.10%	6.41%	8.38%	8.82%	7.61%	6.60%	-3.10%	-5.88%	3.42%	3.88%	5.59%	12.30%	16.27%	12.59%	14.22%	14.97%	16.09%	25.46%	15.60%	12.58%	11.46%	12.03%	5.90%	9.83%	11.56%	1.57%	16.37%	19.84%	20.01%	20.45%	18.49%	15.70%	0.00%
Income Tax Expense	34.31M	26.00M	20.25M	-6.56M	10.63M	18.61M	14.06M	-1.21M	2.16M	14.27M	1.25M	11.10M	22.61M	30.10M	22.90M	25.70M	25.32M	23.23M	37.81M	20.20M	16.49M	10.23M	10.78M	10.09M	8.47M	11.40M	3.90M	17.70M	19.30M	18.90M	19.30M	15.20M	9.70M	0.00
Net Income	117.56M	115.40M	43.38M	79.47M	76.53M	55.02M	45.57M	-26.27M	-55.62M	16.90M	35.15M	38.80M	66.89M	79.98M	58.38M	59.30M	51.98M	49.11M	69.08M	39.64M	29.32M	28.38M	30.03M	7.24M	19.00M	21.10M	-24.80M	33.00M	35.90M	33.60M	31.50M	24.80M	18.00M	0.00
Net Income Ratio	8.98%	9.87%	4.37%	9.13%	7.74%	5.69%	5.04%	-2.96%	-6.11%	1.86%	3.75%	4.35%	9.19%	11.82%	9.04%	9.92%	10.07%	10.92%	16.46%	10.33%	8.05%	8.42%	9.38%	2.46%	6.84%	7.48%	-8.68%	10.65%	12.90%	12.80%	12.68%	11.47%	10.20%	0.00%
EPS	2.32	2.27	0.85	1.57	1.51	1.07	0.86	-0.51	-1.09	0.33	0.68	0.76	1.30	1.59	1.15	1.17	1.00	0.92	1.29	0.77	0.60	0.57	0.57	0.14	0.30	0.39	-0.47	0.61	0.66	0.61	0.56	0.45	0.33	0.26
EPS Diluted	2.29	2.24	0.84	1.55	1.48	1.04	0.85	-0.51	-1.09	0.32	0.67	0.74	1.30	1.56	1.12	1.14	0.97	0.89	1.25	0.75	0.60	0.56	0.56	0.14	0.29	0.39	-0.47	0.60	0.65	0.59	0.55	0.44	0.32	0.25
Weighted Avg Shares Out	50.71M	50.78M	51.05M	50.69M	50.69M	51.53M	52.76M	51.51M	50.91M	51.53M	51.61M	51.35M	50.73M	50.15M	50.90M	50.78M	51.65M	53.49M	52.96M	51.05M	48.87M	49.18M	52.43M	50.60M	52.17M	53.49M	52.77M	54.38M	54.39M	55.54M	55.75M	55.73M	55.38M	55.60M
Weighted Avg Shares Out (Dil)	51.40M	51.42M	51.35M	51.29M	51.82M	52.94M	53.50M	51.52M	50.91M	52.09M	52.38M	52.26M	51.59M	51.19M	52.13M	52.35M	53.49M	55.30M	54.95M	52.85M	49.28M	50.10M	54.31M	52.01M	53.00M	53.77M	53.33M	54.83M	55.23M	56.95M	57.80M	57.01M	57.14M	55.60M